Daunorubicin hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100240

CAS#: 23541-50-6 (HCl)

Description: Daunorubicin hydrochloride is the hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.


Price and Availability

Size
Price

10mg
USD 60
100mg
USD 250
1g
USD 750
10g
USD 2650
100g
USD 12650
Size
Price

25mg
USD 90
200mg
USD 350
2g
USD 1150
20g
USD 4650
Size
Price

50mg
USD 150
500mg
USD 450
5g
USD 1850
50g
USD 7650

Daunorubicin hydrochloride, purity > 99%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100240
Name: Daunorubicin hydrochloride
CAS#: 23541-50-6 (HCl)
Chemical Formula: C27H30ClNO10
Exact Mass:
Molecular Weight: 563.98
Elemental Analysis: C, 57.50; H, 5.36; Cl, 6.29; N, 2.48; O, 28.37


Related CAS #: 23541-50-6 (HCl)   20830-81-3 (free base)    

Synonym: cloridrato de daunorubicina; daunomycin hydrochloride; daunomycinHCL; daunorubicin; daunorubidomycine; rubomycin C; US brand names: Cerubidine; Rubidomycin; Foreign brand names: Cerubidin; Daunoblastin; Daunoblastina; Ondena; Rubilem; Abbreviations: DNM; DNR; DRB; Code names: FI6339; RP13057.

IUPAC/Chemical Name: (8S,10S)-8-acetyl-10-(((2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride.

InChi Key: GUGHGUXZJWAIAS-VGUYFWKPSA-N

InChi Code: InChI=1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17+,22+,27-;/m0./s1

SMILES Code: O=C1C2=C(O)C(C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]4O[C@@H](C)[C@@H](O)[C@@H](N)C4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=O.[H]Cl


Technical Data

Appearance:
Red solid powder

Purity:
>99% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

 Related CAS#
23541-50-6 (Daunorubicin HCl);
20830-81-3 (Daunorubicin free base).


References

1: Vasanthakumar A, Kattusamy K, Prasad R. Regulation of daunorubicin biosynthesis in Streptomyces peucetius - feed forward and feedback transcriptional control. J Basic Microbiol. 2013 Aug;53(8):636-44. doi: 10.1002/jobm.201200302. Epub 2013 Feb 18. Review. PubMed PMID: 23417448.

2: Balendiran GK. Fibrates in the chemical action of daunorubicin. Curr Cancer Drug Targets. 2009 May;9(3):366-9. Review. PubMed PMID: 19442055.

3: Petre CE, Dittmer DP. Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine. 2007;2(3):277-88. Review. PubMed PMID: 18019828; PubMed Central PMCID: PMC2676651.

4: Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005 Jun;46(6):795-802. Review. PubMed PMID: 16019523.

5: Laurent G, Jaffrézou JP. Signaling pathways activated by daunorubicin. Blood. 2001 Aug 15;98(4):913-24. Review. PubMed PMID: 11493433.

6: Portugal J, Martín B, Vaquero A, Ferrer N, Villamarín S, Priebe W. Analysis of the effects of daunorubicin and WP631 on transcription. Curr Med Chem. 2001 Jan;8(1):1-8. Review. PubMed PMID: 11172687.

7: Hui YF, Cortes JE. Chest and back pain associated with a six-hour infusion of liposomal daunorubicin. Ann Pharmacother. 2000 Jun;34(6):810-1. Review. PubMed PMID: 10860143.

8: Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999 Apr 1;57(7):727-41. Review. PubMed PMID: 10075079.

9: Chew T, Jacobs M. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma. Oncology (Williston Park). 1996 Jun;10(6 Suppl):28-33; discussion 37-8. Review. PubMed PMID: 16871707.

10: Speth PA, Minderman H, Haanen C. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol. 1989 Feb;16(1 Suppl 2):2-9. Review. PubMed PMID: 2648580.

11: Tohda S, Kobayashi H, Suzuki T, Koyama T, Kamiyama T, Nakamura Y, Miura O, Maruyama Y, Katoh A, Murakami N, et al. [Acute pericarditis caused by daunorubicin in acute myelocytic leukemia]. Rinsho Ketsueki. 1988 Jun;29(6):874-8. Review. Japanese. PubMed PMID: 3047456.

12: Skovsgaard T. Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur J Haematol Suppl. 1987;47:7-20. Review. PubMed PMID: 3552720.

13: Riggs CE Jr. Clinical pharmacology of daunorubicin in patients with acute leukemia. Semin Oncol. 1984 Dec;11(4 Suppl 3):2-11. Review. PubMed PMID: 6390687.

14: Trouet A, Jollès G. Targeting of daunorubicin by association with DNA or proteins: a review. Semin Oncol. 1984 Dec;11(4 Suppl 3):64-72. Review. PubMed PMID: 6095457.

15: Aubel-Sadron G, Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie. 1984 May;66(5):333-52. Review. PubMed PMID: 6380596.

16: Stroshane RM. Production of daunorubicin. Adv Biotechnol Processes. 1984;3:141-61. Review. PubMed PMID: 6399841.

17: Weiss RB, Bruno S. Daunorubicin treatment of adult solid tumors. Cancer Treat Rep. 1981;65 Suppl 4:25-8. Review. PubMed PMID: 7049378.

18: Maral RJ, Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treat Rep. 1981;65 Suppl 4:9-18. Review. PubMed PMID: 6809317.

19: Davis HL, Davis TE. Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treat Rep. 1979 May;63(5):809-15. Review. PubMed PMID: 378369.